Clear Understanding of STENDRA OTC Label to be Key Element in OTC Development Program Company is Pursuing

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today provides positive results from its over-the-counter (OTC) draft label comprehension study for its erectile dysfunction (ED) drug STENDRA (avanafil), which demonstrate understanding of the messages therein. These results suggest that the draft drug facts labeling language as written may be appropriate for submission to the FDA for review for over-the-counter labeling.

The Pivotal Label Comprehension Study compiled 453 label comprehension interviews – including a significant cohort of low health literacy individuals – to determine comprehension of draft drug facts labeling for STENDRA. In summary, the proposed over-the-counter (OTC) labeling was well understood, according to the study parameters, by those consumers who participated. More than 95% of participants provided correct or acceptable responses to questions that evaluated comprehension of nine primary communication messages. These included whether STENDRA can be used if an individual takes nitrate medication or does not have erectile dysfunction. Interestingly, comprehension among the low health literacy individuals, while modestly lower than those with better health understanding, still demonstrated a high level of comprehension.

“The results of this label comprehension study help us to continue to solidify our plans to apply to the FDA to help expand access for STENDRA beyond the prescription model, and, if approved by the FDA, to make STENDRA potentially the first prescription-grade ED medication to become available over-the-counter in the United States,” commented Fady Boctor, Petros’s President and Chief Commercial Officer. “The switch to OTC is one of many approaches we are currently exploring to expand access to STENDRA. We remain steadfast in our dedication to men with ED by providing new and innovative options to help them safely, securely, and discreetly obtain this medication.”

It is estimated that only about 25% of the approximately 30 million men suffering from erectile dysfunction in the U.S. have received oral erectile dysfunction therapy.

About STENDRA ® (avanafil)

STENDRA ® (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction. STENDRA ® is not for use in women or children. It is not known if STENDRA ® is safe and effective in women or children under 18 years of age. 100-mg and 200-mg tablets can be taken as early as ~15 minutes before sexual activity. STENDRA ® works only with sexual stimulation and should not be taken more than once a day. STENDRA ® can be taken with or without food; do not drink too much alcohol when taking STENDRA ® (for example, more than 3 glasses of wine or 3 shots of whiskey) as it can increase chances of side effects. Of people enrolled in clinical trials, 1.4%, 2.0%, and 2.0%, stopped taking STENDRA ® (50 mg, 100 mg, or 200 mg, respectively) due to side effects compared to 1.7% on placebo. STENDRA ® was designed and developed expressly for erectile dysfunction. Currently, STENDRA ® is covered for ~75% of commercially insured lives, with a co-pay as low as $0. For more information visit: https://STENDRA.com/.

STENDRA ® Important Risk Information
STENDRA ® can cause your blood pressure to drop suddenly to an unsafe level if it is taken with certain other medicines. A sudden drop in blood pressure can cause you to feel dizzy, faint, or have a heart attack or stroke.

Do not take STENDRA ® if you:

  • take medicines called nitrates, which are used to treat chest pain (angina)
  • use street drugs called "poppers," such as amyl nitrate and butyl nitrate
  • take medicines called guanylate cyclase stimulators, which include Adempas ® (riociguat), a medicine that treats pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
  • are allergic to avanafil or any of the ingredients in STENDRA ®

Stop sexual activity and get medical help right away if you have symptoms such as chest pain, dizziness, or nausea during sex. Sexual activity can put an extra strain on your heart, especially if your heart is already weak from a heart attack or heart disease. Discuss your health with your healthcare provider to ensure you are healthy enough for sex.
STENDRA ® can cause serious side effects.
Uncommonly reported side effects include:

  • An erection that will not go away (priapism). If you have an erection that lasts more than 4 hours, get medical help right away.
  • Sudden vision loss in one or both eyes. Sudden vision loss in one or both eyes can be a sign of a serious eye problem called non-arteritic anterior ischemic optic neuropathy (NAION). It is uncertain whether PDE5 inhibitors directly cause vision loss. Stop taking STENDRA ® and call your healthcare provider right away if you have sudden vision loss in one or both eyes.
  • Sudden hearing decrease or hearing loss. Some people may also have ringing in their ears (tinnitus) or dizziness.

Before you take STENDRA ® , tell your healthcare provider if you:

  • have or have had heart problems such as a heart attack, irregular heartbeat, angina, or heart failure; have had heart surgery within the last 6 months; have had a stroke; have low blood pressure, or high blood pressure that is not controlled; have a deformed penis shape
  • have had an erection that lasted for more than 4 hours; have problems with your blood cells, such as sickle cell anemia, multiple myeloma, or leukemia; have retinitis pigmentosa, a rare genetic (runs in families) eye disease; have ever had severe vision loss, including an eye problem called non-arteritic anterior ischemic optic neuropathy (NAION); have bleeding problems; have or have had stomach ulcers; have liver problems; have kidney problems or are having kidney dialysis; or have any other medical conditions

Tell your healthcare provider about all of the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. STENDRA ® may affect the way other medicines work, and other medicines may affect the way STENDRA ® works, which may cause side effects. Especially tell your healthcare provider if you take any of the following:

  • medicines called nitrates
  • medicines called guanylate cyclase stimulators, such as riociguat
  • medicines called HIV protease inhibitors, such as ritonavir (Norvir ® ), indinavir (Crixivan ® ), saquinavir (Fortavase ® or Invirase ® ), or atazanavir (Reyataz ® )
  • some types of oral antifungal medicines, such as ketoconazole (Nizoral ® ) and itraconazole (Sporanox ® )
  • some types of antibiotics, such as clarithromycin (Biaxin ® ), telithromycin (Ketek ® ), or erythromycin
  • medicines called alpha-blockers. These include terazosin (Hytrin ® ), tamsulosin HCl (Flomax ® ), doxazosin (Cardura ® ), prazosin HCl (Minipress ® ), alfuzosin HCl (UroXatral ® ), dutasteride and tamsulosin HCl (Jalyn ® ), or silodosin (Rapaflo ® ). Alpha-blockers are sometimes prescribed for prostate problems or high blood pressure. In some patients, the use of STENDRA ® with alpha-blockers can lead to a drop in blood pressure or fainting
  • other medicines that treat high blood pressure
  • other medicines or treatments for ED

Do not drink too much alcohol (for example, more than 3 glasses of wine or 3 shots of whiskey) when taking STENDRA ® , as this can lead to increased chances of headache, dizziness, increased heart rate, or lowered blood pressure.
STENDRA ® does not protect against sexually transmitted diseases, including HIV.
The most common side effects of STENDRA ® are headache, flushing, stuffy or runny nose, sore throat, and back pain.
Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects of STENDRA ® . For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects.
Please see full Prescribing Information and Patient Information .

About Petros Pharmaceuticals

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health, and substance use disorders.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based upon Petros Pharmaceuticals, Inc.’s (“Petros,” “we,” “our,” “us” or the “Company”) management’s assumptions, expectations, projections, intentions and beliefs about future events. In some cases, predictive, future-tense or forward-looking words such as “intend,” “develop,” “goal,” “plan,” “predict,” “may,” “will,” “project,” “estimate,” “anticipate,” “believe,” “expect,” “continue,” “potential,” “opportunity,” “forecast,” “should” and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of risks and uncertainties, including, without limitation, Petros’ ability to execute on its business strategy, including its plans to develop and commercialize its product candidates; Petros’ ability to comply with obligations as a public reporting company; the ability of Petros to timely and effectively implement controls and procedures required by Section 404 of the Sarbanes-Oxley Act of 2002; the risk that the financial performance of Petros may not be as anticipated by the merger transactions that resulted in the Company’s creation; risks resulting from Petros’ status as an emerging growth company, including that reduced disclosure requirements may make shares of Petros common stock less attractive to investors; risks related to Petros’ history of incurring significant losses; risks related to Petros’ dependence on the commercialization of a single product, STENDRA ® , and on a single distributor thereof; risks related to the termination of Petros’ commercial supply agreement with Vivus, including the risk that Petros may not be able to obtain sufficient quantities of STENDRA ® in a timely manner or on commercially viable terms; risks related to Petros’ ability to obtain regulatory approvals for, or market acceptance of, any of its products or product candidates; and the expected or potential impact of the novel coronavirus (“COVID-19”) pandemic, including the emergence of new variants, such as the Delta variant, and the related responses of governments, consumers, customers, suppliers, employees and the Company, on our business, operations, employees, financial condition and results of operations. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in the Company’s periodic reports and in other filings that the Company has filed, or may file, with the U.S. Securities and Exchange Commission (the “SEC”) under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere. The Company cautions readers that the forward-looking statements included in this press release represent our beliefs, expectations, estimates and assumptions only as of the date of hereof and are not intended to give any assurance as to future results. New factors emerge from time to time, and it is not possible for us to predict all of these factors. Further, the Company cannot assess the effect of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement. Accordingly, you should not unduly rely on any forward-looking statements.

The Company undertakes no obligation to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events, a change in our views or expectations or otherwise, except as required by federal securities laws.

CONTACTS:

Investors:
CORE IR
ir@petrospharma.com

Media:
Jules Abraham
CORE IR
917-885-7378
pr@coreir.com